LongevityResearch Market

NAD+

Nicotinamide adenine dinucleotide, a coenzyme central to cellular energy metabolism and DNA repair, studied for age-related decline and its role in sirtuin activation.

Anti-AgingCellular EnergyDNA RepairSirtuins

Also referenced as: Nicotinamide Adenine Dinucleotide, NAD

Also appears in: Metabolic · Tissue repair

Price compare
268 tracked offers across 268 vendors · 25 dosages
Best trust-adjusted value: Peptide Plugs · Strong trust · $0.03/mg
From
$0.03/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$0.04/mg
Market median$0.12/mg
Current coverage83 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when NAD+ crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence420 certificate records mentioning this compound or product name234 provider-linked · 348 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Longevity

Primary research area: Longevity. Also surfaces under Metabolic · Tissue repair for browsing and discovery.

Aliases
2

Nicotinamide Adenine Dinucleotide, NAD

Signal depth
Medium

FDA label signal · 748 trials · 58099 PubMed results

Promising
Research evidence

NAD+ has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

NAD+ has 8 name-matched clinical trials (highest phase: Phase 2) and 58099 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Large RCT
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
PHASE2 · RandomizedThe NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical ParkinsonismPHASE2Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 SyndromeNA · RandomizedEffect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy AdultsNature · 3,511 citationsTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylaseNature · 3,280 citationsAMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityCirculation Research · 2,884 citationsNAD(P)H Oxidase
Evidence history
  1. 2026-07-31Preclinical→PromisingBand Preclinical → Promising; +37 trials; +5 PubMed
  2. 2026-07-30Promising→PreclinicalBand Promising → Preclinical; -15 trials; +10 PubMed
  3. 2026-07-09PromisingFirst graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for hundreds of metabolic reactions including glycolysis, the citric acid cycle, and oxidative phosphorylation. It also serves as a substrate for sirtuins (SIRT1–7) and poly(ADP-ribose) polymerases (PARPs), which regulate DNA repair, gene expression, and cellular stress responses.

Why it matters for aging research

NAD+ levels decline with age across multiple tissues. This decline has been linked to:

  • Mitochondrial dysfunction — reduced NAD+ impairs the electron transport chain and shifts cells toward less efficient energy production (Gomes et al., Cell, 2013)
  • DNA repair deficits — PARPs consume NAD+ during DNA damage repair; chronic low-grade damage depletes the pool (Fang et al., Cell Metabolism, 2014)
  • Sirtuin activity — SIRT1 and SIRT3 require NAD+ as a co-substrate; declining NAD+ reduces their deacetylase activity (Imai & Guarente, Trends in Cell Biology, 2014)

Precursor vs. direct supplementation

Most oral NAD+ research uses precursors rather than direct NAD+ because the molecule itself has poor oral bioavailability:

  • NMN (nicotinamide mononucleotide) — a direct NAD+ precursor; human trials show it raises blood NAD+ levels (Yoshino et al., Science, 2021)
  • NR (nicotinamide riboside) — another precursor; the CHROMADIET trial showed dose-dependent NAD+ increases in humans (Martens et al., Nature Communications, 2018)
  • IV NAD+ — bypasses oral absorption; used in clinical settings but not well-studied in controlled trials
  • Subcutaneous NAD+ — available from research peptide vendors as injectable formulations (typically 100–500mg vials)

Research status

NAD+ biology is extensively published but injectable NAD+ supplementation specifically has limited clinical trial data. Key references:

  • Yoshino et al. (2021) showed NMN supplementation improved muscle insulin sensitivity in prediabetic women (Science, 372(6547):1224–1229)
  • Rajman et al. (2018) reviewed therapeutic potential of NAD+-boosting molecules (Cell Metabolism, 27(3):529–547)
  • Covarrubias et al. (2021) linked NAD+ decline to age-related inflammation via CD38 upregulation (Nature Metabolism, 3:1–11)

Key considerations

  • Injectable NAD+ from research vendors is not pharmaceutical-grade and has no FDA oversight
  • The relationship between raising blood NAD+ and functional outcomes in humans is still being established
  • Oral precursors (NMN, NR) have more human trial data than injectable NAD+ formulations